The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device
Open accessAbstract
OBJECTIVE: To assess efficacy of the levonorgestrel-releasing intrauterine device (LNG-IUD) for treatment of complex atypical hyperplasia or low-grade endometrial cancer. METHODS: This retrospective case series included all patients treated with the LNG-IUD for complex atypical hyperplasia or early-grade endometrial cancer from January 2003 to June 2013. Response rates were calculated and the association of response with clinicopathologic factors, including age, body mass index, and uterine size, was determined. RESULTS: Forty-six patients diagnosed with complex atypical hyperplasia or early-grade endometrial cancer were treated with the LNG-IUD. Of 32 evaluable patients at the 6-month time point, 15 had complex atypical hyperplasia (47%), nine had G1 endometrial cancer (28%), and eight had grade 2 endometrial cancer (25%). Overall response rate was 75% (95% CI 57–89) at 6 months; 80% (95% CI 52–96) in complex atypical hyperplasia, 67% (95% CI 30–93) in grade 1 endometrial cancer, and 75% (CI 35–97) in grade 2 endometrial cancer. Of the clinicopathologic features evaluated, there was a trend toward the association of lack of exogenous progesterone effect in the pathology specimen with nonresponse to the IUD (P=.05). Median uterine diameter was 1.3 cm larger in women who did not respond to the IUD (P=.04). CONCLUSION: Levonorgestrel-releasing IUD therapy for the conservative treatment of complex atypical hyperplasia or early-grade endometrial cancer resulted in return to normal histology in a majority of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Cited by
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Makker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
Self-citationLu, K. H., & Broaddus, R. R. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1514010 · Cited by 663
Self-citation
Metadata
- Authors
- Pal, N., Broaddus, R. R., Urbauer, D. L., Balakrishnan, N., Milbourne, A., Schmeler, K. M., Meyer, L. A., Soliman, P. T., Lu, K. H., Ramirez, P. T., Ramondetta, L., Bodurka, D. C., & Westin, S. N.
- Venue
- Obstetrics & Gynecology
- Published
- 2018-01
- Volume
- 131
- Issue
- 1
- Pages
- 109-116
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2771467906
- Cited by
- 192
- References
- 1
- FWCI
- 16.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. https://app.cochat.ai/papers/10.1097/aog.0000000000002390
- The paper
- Pal, N., Broaddus, R. R., Urbauer, D. L., Balakrishnan, N., Milbourne, A., Schmeler, K. M., Meyer, L. A., Soliman, P. T., Lu, K. H., Ramirez, P. T., Ramondetta, L., Bodurka, D. C., & Westin, S. N. (2018). Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstetrics & Gynecology. https://doi.org/10.1097/aog.0000000000002390
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.